U.S. Markets closed

Shire plc (SHPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
148.44+0.73 (+0.49%)
At close: 4:00PM EDT

150.00 +1.56 (1.05%)
After hours: 4:31PM EDT

People also watch
ALXNJAZZBMRNBAXREGN
Full screen
Previous Close147.71
Open148.91
Bid149.00 x 100
Ask155.69 x 100
Day's Range148.01 - 149.73
52 Week Range147.28 - 209.22
Volume1,719,962
Avg. Volume1,329,889
Market Cap44.91B
Beta1.65
PE Ratio (TTM)152.25
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.92 (0.63%)
Ex-Dividend Date2017-03-08
1y Target EstN/A
Trade prices are not sourced from all markets
  • Shire Files Marketing Application for Lifitegrast in Europe
    Zacks3 hours ago

    Shire Files Marketing Application for Lifitegrast in Europe

    Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.

  • American City Business Journals2 days ago

    Shire applies for European approval of potential blockbuster eye drop

    One of the state’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S. The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016. It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by Allergan plc (AGN) that’s approved to increase tear production due to inflammation.

  • TheStreet.com2 days ago

    Shire Gains as it Seeks European Approval For Dry Eye Treatment

    The drug would be the first such treatment in Europe.